SCHEMBL4304567

SCHEMBL4304567

COC(=O)CNC(=O)c1nc2cc(Br)ccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.60
EGFR P00533 1/20 0.45
KDM4E B2RXH2 3/20 0.41
MAPT P10636 2/20 0.40
PKM P14618 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
STAMBP O95630 1/20 0.39
GAA P10253 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39
ROCK2 O75116 1/20 0.38
PRKACA P17612 1/20 0.38
PRKACG P22612 1/20 0.38
PRKACB P22694 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4305878 0.86 EGLN1 (0.81) EGLN1KDM4EMAPTHRH4HRH3
SCHEMBL4303744 0.82 KDM4E (0.57) EGLN1KDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL13747392 0.80 EGLN1 (0.56) EGLN1KDM4EMAPTGAAALDH1A1
SCHEMBL13748011 0.80 MMP2 (0.50) EGLN1EGFRMAPTGAAMMP2
SCHEMBL30643039 0.77 EGLN1 (0.53) EGLN1MAPTMMP13ROCK2PRKACA
SCHEMBL29086767 0.77 EGLN1 (0.53) EGLN1MAPTMMP13ROCK2PRKACA
SCHEMBL30912938 0.77 EGLN1 (0.53) EGLN1MAPTMMP13ROCK2PRKACA
SCHEMBL15747083 0.76 EGLN1 (0.44) EGLN1KDM4EGAAMMP2MMP9
SCHEMBL4303666 0.75 EGLN1 (1.00) EGLN1EGFRKDM4EMAPTHRH4
SCHEMBL13625961 0.75 EGLN1 (0.82) EGLN1KDM4EMAPTMMP13ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
WO-2009134754-A1 BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors EGLN3, EGLN2, P4HA1 EGLN1 5/4885EGFR 4375/4885KDM4E 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.